Latest News
Feb 12, 2019

Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ADVAIR DISKUS®, Wixela™ Inhub™ (fluticasone propionate and...

Feb 11, 2019

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on...

Jan 31, 2019

Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the first...

Dec 20, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on...

Dec 17, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Delayed-Release Tablets USP, 1.2 g, a generic version of Shire's Lialda® Delayed-Release...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected